Shots:

• In Jul 2020- following the pCPA agreement Riximyo is now reimbursed through Limited Use as well as the Exceptional Access Program while funding will be done by Cancer Care Ontario. Additionally- from Aug 01- 2020- the BC cancer will be responsible for reimbursement of Riximyo as per British Columbia
• The patient support program will be initiated to provide patients the guidance with reimbursement navigation- financial assistance- administrative support- as well as education for patients
• On Apr 28- 2020- Riximyo received HC approval a mAb or the treatment of NHL and CLL- as well as the autoimmune disease RA. On Apr 21- 2020- Ziextenzo received HC approval a long-acting form of recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) for to decrease the incidence of infection- as manifested by febrile neutropenia- in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic agents

Ref: GlobeNewswire | Image: Behance